Polymem

Polymem is a privately held commercial-stage company specializing in innovative wound care and drug delivery via its proprietary hydrophilic polyurethane matrix platform. Its core technology integrates cleansing, moisturizing, and absorbing agents into a single dressing, aiming to control inflammation, reduce pain, and accelerate healing across a broad spectrum of acute and chronic wounds. With products cleared by the FDA and commercially available globally, Polymem targets the large and growing advanced wound care market by addressing key clinician and patient needs for simplified, effective wound management. The company appears to be revenue-generating, leveraging a direct-to-consumer and professional distribution model.

Proprietary hydrophilic polyurethane foam matrix pre-loaded with a wound cleanser, moisturizer, and superabsorbent, activated by wound exudate to provide continuous cleansing, debridement, moisture management, and pain relief.

Polymem competes in the advanced wound dressing segment against major players like 3M, Smith & Nephew, Mölnlycke, and ConvaTec, who offer extensive foam, hydrocolloid, and antimicrobial dressing lines. Its differentiation lies in its multifunctional, all-in-one design that actively manages the wound environment, contrasting with many passive absorbent dressings.